Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is aggressive therapy effective for lupus?

J H Klippel1

  • 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.

Rheumatic Diseases Clinics of North America
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is malignancy a major concern in rheumatoid arthritis patients?

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Predicting who will get lupus nephritis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.

Rheumatology (Oxford, England)·2007
Same author

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.

Arthritis and rheumatism·2002
Same author

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

Annals of internal medicine·2001
Same author

Biologic therapy for rheumatoid arthritis.

The New England journal of medicine·2000
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Intravenous cyclophosphamide effectively treats severe systemic lupus erythematosus, especially lupus nephritis and neurologic disease. Its toxicity profile is favorable compared to other aggressive treatments.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse manifestations.
  • Aggressive immunosuppressive therapies are often required for severe SLE.
  • Intravenous cyclophosphamide has been a cornerstone therapy, particularly for lupus nephritis.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravenous cyclophosphamide for various SLE manifestations.
  • To compare intravenous cyclophosphamide with other immunosuppressive agents, including corticosteroids and oral cyclophosphamide.
  • To assess the role of intravenous cyclophosphamide in neurologic lupus.

Main Methods:

  • Review of available comparative data on intravenous cyclophosphamide efficacy.

Related Experiment Videos

  • Analysis of clinical experience and toxicity profiles.
  • Comparison with high-dose oral and intravenous corticosteroid therapies.
  • Comparison with oral cyclophosphamide and azathioprine regimens.

    • Main Results:

    • Intravenous cyclophosphamide demonstrates superior efficacy to intensive corticosteroid therapies for SLE.
    • Evidence supports its use in acute neurologic lupus, beyond lupus nephritis.
    • Toxicity of intravenous cyclophosphamide is comparable to other aggressive treatments, with acceptable risk.
    • Onset of action may be more rapid than low-dose oral therapies.

    Conclusions:

    • Intravenous cyclophosphamide is a highly effective and relatively safe aggressive therapy for severe SLE.
    • It offers significant benefits over corticosteroids and potentially faster onset than some oral agents.
    • Further research is needed to define the role of emerging therapies.